Literature DB >> 25355295

Rare is frequent and frequent is costly: rare diseases as a challenge for health care systems.

J-Matthias Graf von der Schulenburg1, Martin Frank.   

Abstract

Mesh：

Year:  2015        PMID： 25355295     DOI： 10.1007/s10198-014-0639-8

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN： 1618-7598


× No keyword cloud information.
  11 in total

Review 1.  Orphan drugs and the NHS: should we value rarity?

Authors:  Christopher McCabe; Karl Claxton; Aki Tsuchiya
Journal:  BMJ       Date:  2005-10-29

2.  Are we finally winning the war on cancer?

Authors:  David M Cutler
Journal:  J Econ Perspect       Date:  2008

3.  What is wrong with orphan drug policies?

Authors:  André Côté; Bernard Keating
Journal:  Value Health       Date:  2012-12       Impact factor: 5.725

Review 4.  Orphan drugs policies: a suitable case for treatment.

Authors:  Michael Drummond; Adrian Towse
Journal:  Eur J Health Econ       Date:  2014-05

5.  [Seven years of the National Action League for People with Rare Diseases : NAMSE - a success story?!]

Authors:  Alexandra Halbach; Birgit Schnieders; Karin Knufmann-Happe
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2017-05       Impact factor: 1.513

6.  Assessing the economic challenges posed by orphan drugs.

Authors:  Michael F Drummond; David A Wilson; Panos Kanavos; Peter Ubel; Joan Rovira
Journal:  Int J Technol Assess Health Care       Date:  2007       Impact factor: 2.188

7.  [Cost analysis for ambulatory treatment of cystic fibrosis patients in Germany. Overview of the prospective study results].

Authors:  Daniela Eidt; Thomas Mittendorf; Thomas O F Wagner; Andreas Reimann; J-Matthias Graf von der Schulenburg
Journal:  Med Klin (Munich)       Date:  2009-07-18

8.  Cost-effectiveness of enzyme replacement therapy for Fabry disease.

Authors:  Saskia M Rombach; Carla E M Hollak; Gabor E Linthorst; Marcel G W Dijkgraaf
Journal:  Orphanet J Rare Dis       Date:  2013-02-19       Impact factor: 4.123

9.  Estimating the budget impact of orphan drugs in Sweden and France 2013-2020.

Authors:  Adam Hutchings; Carina Schey; Richard Dutton; Felix Achana; Karolina Antonov
Journal:  Orphanet J Rare Dis       Date:  2014-02-13       Impact factor: 4.123

10.  Cost-effectiveness of enzyme replacement therapy for type 1 Gaucher disease.

Authors:  Laura van Dussen; Marieke Biegstraaten; Carla E M Hollak; Marcel G W Dijkgraaf
Journal:  Orphanet J Rare Dis       Date:  2014-04-14       Impact factor: 4.123
View more
  14 in total

1.  Personalized Medicine and Pay for Performance: Should Pharmaceutical Firms be Fully Penalized when Treatment Fails?

Authors:  Fernando Antoñanzas; Roberto Rodríguez-Ibeas; Carmelo A Juárez-Castelló
Journal:  Pharmacoeconomics       Date:  2018-07       Impact factor: 4.981

2.  Public spending on orphan medicines: a review of the literature.

Authors:  Margit Gombocz; Sabine Vogler
Journal:  J Pharm Policy Pract       Date:  2020-10-13

3.  Abstracts from the 3rd International PPRI Conference 2015: Pharmaceutical Pricing and Reimbursement Policies: Challenges Beyond the Financial Crisis.

Authors: 
Journal:  J Pharm Policy Pract       Date:  2015-10-05

4.  A novel gene network analysis in liver tissues of diabetic rats in response to resistant starch treatment.

Authors:  Zhiwei Wang; Yinghui Zhang; Runge Shi; Zhongkai Zhou; Fang Wang; Padraig Strappe
Journal:  Springerplus       Date:  2015-03-05

5.  Negotiating prices of drugs for rare diseases.

Authors:  Séverine Henrard; Francis Arickx
Journal:  Bull World Health Organ       Date:  2016-08-31       Impact factor: 9.408

6.  Rare Diseases on the Internet: An Assessment of the Quality of Online Information.

Authors:  Frédéric Pauer; Svenja Litzkendorf; Jens Göbel; Holger Storf; Jan Zeidler; Johann-Matthias Graf von der Schulenburg
Journal:  J Med Internet Res       Date:  2017-01-18       Impact factor: 5.428

7.  RD-RAP: beyond rare disease patient registries, devising a comprehensive data and analytic framework.

Authors:  Matthew I Bellgard; Tom Snelling; James M McGree
Journal:  Orphanet J Rare Dis       Date:  2019-07-12       Impact factor: 4.123

8.  How are patients with rare diseases and their carers in the UK impacted by the way care is coordinated? An exploratory qualitative interview study.

Authors:  Amy Simpson; Lara Bloom; Naomi J Fulop; Emma Hudson; Kerry Leeson-Beevers; Stephen Morris; Angus I G Ramsay; Alastair G Sutcliffe; Holly Walton; Amy Hunter
Journal:  Orphanet J Rare Dis       Date:  2021-02-10       Impact factor: 4.123

Review 9.  Rare diseases under different levels of economic analysis: current activities, challenges and perspectives.

Authors:  Sara Cannizzo; Valentina Lorenzoni; Ilaria Palla; Salvatore Pirri; Leopoldo Trieste; Isotta Triulzi; Giuseppe Turchetti
Journal:  RMD Open       Date:  2018-11-12

10.  Cost-effectiveness analysis of using the TBX6-associated congenital scoliosis risk score (TACScore) in genetic diagnosis of congenital scoliosis.

Authors:  Zefu Chen; Zihui Yan; Chenxi Yu; Jiaqi Liu; Yanbin Zhang; Sen Zhao; Jiachen Lin; Yuanqiang Zhang; Lianlei Wang; Mao Lin; Yingzhao Huang; Xiaoxin Li; Yuchen Niu; Shengru Wang; Zhihong Wu; Guixing Qiu; Terry Jianguo Zhang; Nan Wu
Journal:  Orphanet J Rare Dis       Date:  2020-09-15       Impact factor: 4.123
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.